Viveve Medical (VIVE) 10-K 16 Feb 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Feb. 07, 2017	Jun. 30, 2016
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	879,682
Trading Symbol	vivmf
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		10,700,606
Entity Public Float			$ 26,985,811
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 8,086,000	$ 7,360,000
Accounts receivable	2,091,000	593,000
Inventory	2,687,000	1,549,000
Prepaid expenses and other current assets	1,066,000	1,228,000
Total current assets	13,930,000	10,730,000
Property and equipment, net	483,000	239,000
Other assets	136,000	138,000
Total assets	14,549,000	11,107,000
Current liabilities:
Accounts payable	3,086,000	1,432,000
Accrued liabilities	2,186,000	1,293,000
Note payable, current portion	1,867,000	4,446,000
Total current liabilities	7,139,000	7,171,000
Note payable, noncurrent portion	7,762,000	0
Other noncurrent liabilities	53,000	0
Total liabilities	14,954,000	7,171,000
Commitments and contingences (Note 7)
Stockholders’ equity (deficit):
Additional paid-in capital	68,216,000
Accumulated deficit	(68,622,000)	(48,511,000)
Total stockholders’ equity (deficit)	(405,000)	3,936,000
Total liabilities and stockholders’ equity (deficit)	14,549,000	11,107,000
Preferred Stock with Par Value [Member]
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2016; no shares issued	0
Preferred Stock, No Par Value [Member]
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2016; no shares issued	0
Common Stock with Par Value [Member]
Stockholders’ equity (deficit):
Common stock, $0.0001 par value; 75,000,000 shares authorized as of December 31, 2016; 10,661,201 shares issued and outstanding as of December 31, 2016	$ 1,000
Common Stock with No Par Value [Member]
Stockholders’ equity (deficit):
Common stock, $0.0001 par value; 75,000,000 shares authorized as of December 31, 2016; 10,661,201 shares issued and outstanding as of December 31, 2016		$ 52,447,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Preferred Stock with Par Value [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000
Preferred stock, shares issued (in shares)	0
Preferred Stock, No Par Value [Member]
Preferred stock, shares issued (in shares)	0
Preferred stock, no par value (in dollars per share)	$ 0
Common Stock with Par Value [Member]
Common stock, par value (in dollars per share)	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000
Common stock, shares issued (in shares)	10,661,201
Common stock, shares outstanding (in shares)	10,661,201
Common stock, shares issued (in shares)	10,661,201
Common stock, shares outstanding (in shares)	10,661,201
Common Stock with No Par Value [Member]
Common stock, shares issued (in shares)		7,490,288
Common stock, shares outstanding (in shares)		7,490,288
Common stock, no par value (in dollars per share)		$ 0
Common stock, shares issued (in shares)		7,490,288
Common stock, shares outstanding (in shares)		7,490,288

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue	$ 7,141	$ 1,447
Cost of revenue	4,612	985
Gross profit	2,529	462
Operating expenses:
Research and development	8,365	4,988
Selling, general and administrative	12,868	7,464
Total operating expenses	21,233	12,452
Loss from operations	(18,704)	(11,990)
Interest expense, net	(1,370)	(415)
Other expense, net	(37)	(21)
Comprehensive and net loss	$ (20,111)	$ (12,426)
Net loss per share:
Basic and diluted (in dollars per share)	$ (2.18)	$ (2.47)
Weighted average shares used in computing net loss per common share
Basic and diluted (in shares)	9,222,348	5,023,080

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	May 2015 Private Placement Offering [Member]Common Stock Including Additional Paid in Capital [Member]	May 2015 Private Placement Offering [Member]	November 2015 Private Placement Offering [Member]Common Stock Including Additional Paid in Capital [Member]	November 2015 Private Placement Offering [Member]	Rights to Shares [Member]Common Stock Including Additional Paid in Capital [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Including Additional Paid in Capital [Member]	Retained Earnings, Appropriated [Member]	Total
Balances as of January 1, 2015 (in shares) at Dec. 31, 2014								2,293,057
Balances as of January 1, 2015 at Dec. 31, 2014								$ 35,244	$ (36,085)	$ (841)
Private placement offering, net of issuance costs (in shares)	4,054,062		1,071,679		70,755
Private placement offering, net of issuance costs	$ 11,040	$ 11,040	$ 5,393	$ 5,393
Issuance of warrants to employees for performance bonuses								286		286
Issuance of warrants to vendors and service providers								251		251
Issuance of warrant in connection with note payable								10		10
Stock-based compensation expense								$ 220		220
Exercise of warrant (in shares)								735
Exercise of warrant								$ 3		3
Comprehensive and net loss									(12,426)	(12,426)
Balances (in shares) at Dec. 31, 2015						0		7,490,288
Balances at Dec. 31, 2015						$ 0	$ 0	$ 52,447	(48,511)	3,936
Issuance of restricted stock awards to employees for performance bonuses
Private placement offering, net of issuance costs (in shares)						3,105,000
Private placement offering, net of issuance costs							13,886			13,886
Issuance of warrants to vendors and service providers										162
Issuance of warrant in connection with note payable							350			350
Stock-based compensation expense							707	$ 188		895
Exercise of warrant (in shares)						35,490		6,250
Exercise of warrant							65	$ 27		92
Comprehensive and net loss									(20,111)	(20,111)
Balances (in shares) at Dec. 31, 2016						10,661,201		0
Balances at Dec. 31, 2016						$ 1	68,216		$ (68,622)	(405)
Reverse stock split - rounding adjustment (in shares)								2,361
Issuance of restricted stock awards to employees for performance bonuses								$ 246		246
Issuance of restricted stock awards to directors and consultants (in shares)						18,792
Issuance of restricted stock awards to directors and consultants							125			125
Issuance of warrants							20	$ 142		$ 162
Exercise of stock options (in shares)								3,020		3,020
Exercise of stock options								$ 14		$ 14
Reclassification upon change in corporate domicile (in shares)						7,501,919		(7,501,919)
Reclassification upon change in corporate domicile						$ 1	$ 53,063	$ (53,064)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (20,111,000)	$ (12,426,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	111,000	77,000
Stock-based compensation	981,000	220,000
Restricted stock award granted to consultant	39,000
Fair value of warrants issued	162,000	251,000
Fair value of warrants issued to employees for bonuses		286,000
Non-cash interest expense	456,000	197,000
Changes in assets and liabilities:
Accounts receivable	(1,498,000)	(587,000)
Inventory	(1,237,000)	(1,438,000)
Prepaid expenses and other current assets	162,000	(879,000)
Other noncurrent assets	2,000	18,000
Accounts payable	1,654,000	1,016,000
Accrued liabilities	1,192,000	1,070,000
Net cash used in operating activities	(18,087,000)	(12,195,000)
Cash flows from investing activities:
Purchase of property and equipment	(256,000)	(109,000)
Net cash used in investing activities	(256,000)	(109,000)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	13,886,000	16,433,000
Proceeds from note payable	9,910,000	2,500,000
Repayments of note payable	(4,833,000)	(167,000)
Proceeds from exercise of warrants	92,000	3,000
Proceeds from exercise of stock options	14,000
Net cash provided by financing activities	19,069,000	18,769,000
Net increase in cash and cash equivalents	726,000	6,465,000
Cash and cash equivalents - beginning of period	7,360,000	895,000
Cash and cash equivalents - end of period	8,086,000	7,360,000
Supplemental disclosure:
Cash paid for interest	803,000	196,000
Cash paid for income taxes	1,000	1,000
Supplemental disclosure of cash flow information as of end of period:
Issuance of warrant in connection with note payable	350,000	10,000
Issuance of restricted stock awards to employees for performance bonuses	246,000
Net transfer of equipment from inventory to property and equipment	$ 99,000	$ 20,000

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) competes in the women’s health industry by marketing Geneveve™ as a way to improve the overall sexual well-being and quality of life of women suffering from vaginal laxity. Public Offering On June 17, 2016, “June 2016 3,105,000 $5.00 $15,525,000. $13,886,000. Change of Corporate Domicile On May 9, 2016, May 10, 2016, $0.0001 Private Placements On November 24, 2015, “November 2015 1,071,679 $5.60 $6,000,000 $5,393,000. On May 14, 2015, “May 2015 4,054,062 $2.96 $12,000,000 $11,040,000. Liquidity and Management P lans The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2016, $8,086,000 $6,791,000. $68,622,000 December 31, 2016. six Management of the Company intends to raise additional funds through the issuance of equity securities. There can be no assurance that such financing will be available or on terms which are favorable to the Company. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations. Accounting Standards Update (“ASU”) 2015 03 January 1, 2016. December 31, 2015. $387,000 December 31, 2015 Reverse Stock Split On April 15, 2016, 1 8 8 one 8 1 1 8 1 8 Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. The Company’s products may The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal laxity that it refers to as the Geneveve™, which includes the Viveve System™, single-use treatment tips and other ancillary consumables. The Company outsources the manufacture and repair of the Viveve System to a single contract manufacturer. Also, certain other components and materials that comprise the Geneveve are currently manufactured by a single supplier or a limited number of suppliers. A significant supply interruption or disruption in the operations of the contract manufacturer or these third During the year ended December 31, 2016, three 78% December 31, 2015, four 87% December 31, 2016, three 81% December 31, 2015, three 86% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not interest bearing. six may six The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectibility of its accounts receivable in its calculation of the allowance for doubtful accounts. In determining the amount of the allowance, the Company makes judgments about the creditworthiness of customers based on ongoing credit evaluations and assesses current economic trends affecting its customers that might impact the level of credit losses in the future and result in different rates of bad debts than previously seen. The Company also considers its historical level of credit losses. As of December 31, 2016 2015, no Inventory Inventory is stated at the lower of cost or market. lnventory as of December 31, 2016 $181,000 $2,506,000 December 31, 2015 Cost is determined on an actual cost basis on a first first As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2016 2015. Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight line method over their estimated useful lives of three seven Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company has not identified any such impairment losses to date. Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company does not provide its customers with a right of return. Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized. Product Warranty The Company’s products are generally subject to a one Shipping and Handling Costs The Company includes amounts billed for shipping and handling in revenue and shipping and handling costs in cost of revenue. Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2016 2015. Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, prototype materials, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities. Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not likely, the Company establishes a valuation allowance. Management judgment is required in determining the Company’s provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against the net deferred tax assets. The Company recorded a full valuation allowance as of December 31, 2016 2015. The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not believe there are any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within 12 Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2016 2015, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. December 31, 2016 2015 Stock options to purchase common stock 1,909,764 1,022,195 Warrants to purchase common stock 425,274 383,321 Restricted common stock awards 58,155 - Recently Issued and Adopted Accounting Standards In May 2014, 2014 09, 606).” five December 15, 2017. January 1, 2017 January 1, 2018, January 1, 2017 2015 14); 2016 08); 2016 10); 2016 10). May 2016, 2016 12, 606) May 2014. In August 2014, 2014 15, 205 40): December 31, 2016 December 31, 2016. 12 In July 2015, 2015 11, 2015 11”). 2015 11 first January 1, 2017 In February 2016, 2016 02, 842)”. December 15, 2018, In March 2016, 2016 09, 718): January 1, 2017 In August 2016, 2016 15, 230). zero December 15, 2017, In August 2016, 2016 18, 230). December 15, 2017,

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 Level 2 Pricing is provided by third Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no financial instruments that were measured at fair value on a recurring basis as of December 31, 2016 2015. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of December 31, 2016 2015 There were no changes in valuation techniques from prior periods.

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment, Net Property and equipment, net, consisted of the following as of December 31, 2016 2015 Life December 31, (in years) 2016 2015 Medical equipment 5 $ 657 $ 454 Computer equipment 3 83 56 Furniture and fixtures 7 57 24 797 534 Less: Accumulated depreciation and amortization (314 ) (295 ) Property and equipment, net $ 483 $ 239 Depreciation and amortization expense for the years ended December 31, 2016 2015 $111,000 $77,000,

Note 5 - Accrued Liabilities

Note 5 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accrued Liabilities Accrued liabilities consisted of the following as of December 31, 2016 2015 December 31, December 31, 2016 2015 Accrued bonuses $ 1,102 $ 613 Accrued professional fees 483 388 Accrued payroll and other related expenses 389 113 Accrued interest 65 22 Other accruals 147 157 Total accrued liabilities $ 2,186 $ 1,293

Note 6 - Note Payable

Note 6 - Note Payable	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Note Payable On September 30, 2014, February 19, 2015, May 14, 2015, November 30, 2015 March 18, 2016 “2014 1 $5,000,000, three first $2,500,000 October 1, 2014 $500,000 second February 19, 2015, March 16, 2015 April 6, 2015 $1,500,000. July 15, 2015 $1,000,000 third In connection with the 2014 September 30, 2014, first 10 58,962 $4.24 first 2014 February 2015, second 2014 May 2015, second 10 3,125 $2.96 two July August 2016 8). On June 20, 2016, “2016 $10,000,000 two $7,500,000 $2,500,000. $10,000,000 June 20, 2016. 2014 July 1, 2017 30 30 6.96%, 7.40%. 7.59% December 31, 2016. In connection with the 2016 10 100,402 $4.98 8). All borrowings under the 2016 The Company is also required to meet certain financial and other covenants in connection with the 2016 80% 1.25 1.00. December 31, 2016, October 31, 2016 November 30, 2016 1.25 1.00. January 13, 2017, 2016 13). As of December 31, 2016, Year Ending December 31, 2017 $ 2,719 2018 4,463 2019 4,512 Total payments 11,694 Less: Amount representing interest (1,694 ) Present value of obligations 10,000 Less: Unamortized debt discount (371 ) 9,629 Less: Note payable, noncurrent portion 7,762 Note payable, current portion $ 1,867

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Operating Lease In January 2012, September 2016, March 2012 March 2018. December 31, 2016 2015 $236,000 $210,000, As of December 31, 2016, Year Ending December 31, 2017 $ 303 2018 82 Total minimum lease payments $ 385 Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not breached the agreement and/or the loss is not attributable to the indemnified party’s negligence or willful malfeasance. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may

Note 8 - Common Stock

Note 8 - Common Stock	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Common Stock On June 17, 2016, June 2016 3,105,000 $5.00 $15,525,000. $13,886,000. On November 24, 2015, November 2015 1,071,679 $5.60 $6,000,000 $5,393,000. On May 14, 2015, May 2015 4,054,062 $2.96 $12,000,000 $11,040,000. Warrants for Common Stock As of December 31, 2016, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 91,532 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 425,274 In connection with the September 2014 117,535 $4.24 five five 2016, 25,268 23,560 2015, 735 In connection with the 2014 September 30, 2014, 58,962 $4.24 ten ten $622,000 0%, 77%, 2.5% ten 10 June 2016 2016 December 31, 2016 2015, $387,000 $187,000, August 2016 17,295 In October November 2014, 47,751 $4.24 five 0%, 61.3%, 1.55% 1.65% five December 31, 2015, 1,094 5,157 2016 2015, In February 2015, 75,697 $4.00 ten ten 0%, 77.6%, 2.14% ten In March 2015, 1,454 $2.72 ten ten 0%, 78.9%, 1.94% ten In May 2015, 36,229 $4.24 ten ten 0%, 80.1%, 2.28% ten In conjunction with the second 2014 May 2015, 3,125 $2.96 December 31, 2015, $10,000 September 30, 2015. July 2016 885 In May 2015, 21,585 $4.24 five five 0%, 64.4%, 1.54% five In December 2015, 26,875 $5.60 ten ten 0%, 76.8%, 2.27% ten In April 2016, 25,000 $6.08 ten ten 0%, 72.1%, 1.78% ten In May 2016, 5,000 $7.74 five five 0%, 61.6%, 1.20% five In connection with the 2016 100,402 $4.98 ten ten $350,000 0%, 63.0%, 1.67% ten $90,000, December 31, 2016, $69,000 December 31, 2016, $371,000. The total stock-based compensation expense related to warrants issued was $162,000 $537,000 December 31, 2016 2015,

Note 9 - Summary of Stock Optio

Note 9 - Summary of Stock Options	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards from three 2005 “2005 2006 “2006 2013 “2013 The 2005 December 31, 2016, 1,892 2005 2005 2005 2005 1,892 $116.29 0.73 The 2006 September 23, 2014 2006 2006 2006 2006 0.0080497 0.0010062 2006 2006 0.0080497 0.0010062 2006 38,378 $10.49 5.88 The 2013 2013 2013 may may may 2013 may 10 may four may 424(f) 10% 110% five On August 22, 2016, 2013 2013 737,500 1,262,500 2,000,000 2013 first January, 4% December 23, 2016, 2017 4% 523,209 January 1, 2017. As of December 31, 2016, 2013 1,869,494 10,236 $5.99 9.19 Activity under the 2005 2006 2013 Year Ended December 31, 2016 Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, beginning of period 1,022,195 $ 6.47 9.37 $ 1,194,180 Options granted 978,966 $ 6.00 Options exercised (3,020 ) $ 4.80 Options canceled (88,377 ) $ 7.41 Options outstanding, end of period 1,909,764 $ 6.19 9.12 $ 211,396 Vested and exercisable and expected to vest, end of period 1,761,430 $ 6.22 9.09 $ 204,619 Vested and exercisable, end of period 368,681 $ 7.51 8.04 $ 102,306 The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of December 31, 2016. The options outstanding and exercisable as of December 31, 2016 Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices December 31, 2016 Price Term (Years) December 31, 2016 Price $2.64 12,500 $ 2.64 8.37 5,209 $ 2.64 $3.68 - $3.76 79,376 $ 3.75 8.10 36,382 $ 3.75 $4.80 - $4.92 197,969 $ 4.80 7.80 109,150 $ 4.80 $5.22 595,034 $ 5.22 9.98 7,250 $ 5.22 $6.00 565,628 $ 6.00 8.96 141,412 $ 6.00 $6.24 - $6.40 129,267 $ 6.35 9.15 - $ - $7.00 - $7.92 284,075 $ 7.71 9.49 23,363 $ 7.72 $9.92 38,135 $ 9.92 5.89 38,135 $ 9.92 $56.00 - $296.00 7,780 $ 83.66 0.83 7,780 $ 83.66 1,909,764 $ 6.19 9.12 368,681 $ 7.51 Restricted Stock Awards In January 2016, 39,494 2013 2015 $6.24 one December 31, 2016, none In August 2016, 5,998 2013 $7.89 In September 2016, 25,000 $7.58 one 1/4th December 31, 2016, 6,250 In November 2016, 6,544 2013 $5.91 A total of 89 January 2016 September 2016. The total number of shares pursuant to outstanding RSAs as of December 31, 2016 58,155 Stock-Based Compensation During the years ended December 31, 2016 2015, 919,841 753,880 $2.63 $3.13 December 31, 2016 $5,000. no December 31, 2015. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Year Ended December 31, 2016 2015 Expected term (in years) 5 5 Average volatility 49 % 63 % Risk-free interest rate 1.78 % 1.70 % Dividend yield 0 % 0 % During the year ended December 31, 2016, 59,125 $4.60 no December 31, 2015. no December 31, 2016 2015. The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions: Year Ended December 31, 2016 Expected term (in years) 10 Average volatility 51 % Risk-free interest rate 2.43 % Dividend yield 0 % Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No The following table shows stock-based compensation expense included in the consolidated statements of operations for the years ended December 31, 2016 2015 Year Ended December 31, 2016 2015 Research and development $ 114 $ 18 Selling, general and administrative 867 202 Total $ 981 $ 220 As of December 31, 2016, $3,757,000. 3.27

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10 . Income Taxes No provision for income taxes has been recorded due to the net operating losses incurred from inception to date, for which no benefit has been recorded. A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2016 2015 Income tax provision (benefit) at statutory rate (34 )% (34 )% State income taxes, net of federal benefit (2 )% (6 )% Change in valuation allowance 33 % 39 % Other 3 % 1 % Effective tax rate - % - % The components of the Company’s net deferred tax assets and liabilities are as follows (in thousands): December 31, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 16,888 $ 10,726 Capitalized start up costs 5,944 7,225 Research and development credits 518 248 Accruals and reserves 1,095 497 Total deferred tax assets 24,445 18,696 Deferred tax liabilities: Fixed assets and depreciation (7 ) (8 ) Valuation allowance (24,438 ) (18,688 ) Net deferred tax assets $ - $ - The Company has recorded a full valuation allowance for its deferred tax assets based on it past losses and the uncertainty regarding the ability to project future taxable income. The valuation allowance increased by approximately $5,750,000 $4,822,000 December 31, 2016 2015, As of December 31, 2016, $45,468,000 $24,498,000, 2017. The Company also has federal and California research and development tax credits of approximately $440,000 $454,000, 2027 Utilization of the NOL and research and development credit carryforwards may 382 1986, may 382, 50 three 382. may 382 As of December 31, 2016, not A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2016 2015 Balance at the beginning of the year $ 128 $ 97 Additions based upon tax positions related to the current year 140 31 Balance at the end of the year $ 268 $ 128 If the ending balance of $268,000 December 31, 2016 twelve may The Company files U.S. federal and state income tax returns with varying statutes of limitations. All tax years since inception remain open to examination due to the carryover of unused net operating losses and tax credits.

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11. Related Party Transactions In June 2006, October 4, 2007. 300 December 31, 2016, 345 37,500 $6,485,000 $3,446,000 December 31, 2016 2015,

Note 12 - Segments and Geograph

Note 12 - Segments and Geographic Information	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	12 . Segments and Geographic Information The Company has determined that it operates as a single operating and reportable segment. Revenue from unaffiliated customers by geographic area was as follows (in thousands): Year Ended December 31, 2016 2015 Asia $ 4,946 889 Europe and Middle East 1,489 551 Latin America 382 - United States 315 - Canada 9 5 Other - 2 Total $ 7,141 $ 1,447 The Company determines geographic location of its revenue based upon the destination of shipments of its products. The Company’s long-lived assets by geographic area were as follows (in thousands): Year Ended December 31, 2016 2015 United States $ 370 $ 100 Europe 72 99 Asia 39 32 Canada 2 8 Total $ 483 $ 239 Long-lived assets, comprised of property and equipment, are reported based on the location of the assets at each balance sheet date.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	13 . Subsequent Events Amendment to Loan Agreement On January 13, 2017, 2016 2016 October 31, 2016 November 30, 2016. 1.25 1.00, $2,000,000, 1.25 1.00. Sublease Agreement and Relocation of Corporate Headquarters to Englewood, Colorado On February 1, 2017, 12,400 January 26, 2017. first 2017 The term of the Sublease will commence on the later of (i) 120 tenant 36 may The monthly base rent under the Sublease will be equal to $20.50 first $21.12 21.75 second third $22,000. $88,000 tenant

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reclassification, Policy [Policy Text Block]	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations. Accounting Standards Update (“ASU”) 2015 03 January 1, 2016. December 31, 2015. $387,000 December 31, 2015
Reverse Stock Split, Policy [Policy Text Block]	Reverse Stock Split On April 15, 2016, 1 8 8 one 8 1 1 8 1 8
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. The Company’s products may The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal laxity that it refers to as the Geneveve™, which includes the Viveve System™, single-use treatment tips and other ancillary consumables. The Company outsources the manufacture and repair of the Viveve System to a single contract manufacturer. Also, certain other components and materials that comprise the Geneveve are currently manufactured by a single supplier or a limited number of suppliers. A significant supply interruption or disruption in the operations of the contract manufacturer or these third During the year ended December 31, 2016, three 78% December 31, 2015, four 87% December 31, 2016, three 81% December 31, 2015, three 86%
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight line method over their estimated useful lives of three seven
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not interest bearing. six may six The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectibility of its accounts receivable in its calculation of the allowance for doubtful accounts. In determining the amount of the allowance, the Company makes judgments about the creditworthiness of customers based on ongoing credit evaluations and assesses current economic trends affecting its customers that might impact the level of credit losses in the future and result in different rates of bad debts than previously seen. The Company also considers its historical level of credit losses. As of December 31, 2016 2015,
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or market. lnventory as of December 31, 2016 $181,000 $2,506,000 December 31, 2015 Cost is determined on an actual cost basis on a first first As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2016 2015.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company has not identified any such impairment losses to date.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company does not provide its customers with a right of return.
Revenue Recognition, Deferred Revenue [Policy Text Block]	Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products are generally subject to a one
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Costs The Company includes amounts billed for shipping and handling in revenue and shipping and handling costs in cost of revenue.
Advertising Costs, Policy [Policy Text Block]	Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2016 2015.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, prototype materials, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities.
Income Tax, Policy [Policy Text Block]	Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not likely, the Company establishes a valuation allowance. Management judgment is required in determining the Company’s provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against the net deferred tax assets. The Company recorded a full valuation allowance as of December 31, 2016 2015. The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not believe there are any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within 12
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2016 2015,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. December 31, 2016 2015 Stock options to purchase common stock 1,909,764 1,022,195 Warrants to purchase common stock 425,274 383,321 Restricted common stock awards 58,155 -
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In May 2014, 2014 09, 606).” five December 15, 2017. January 1, 2017 January 1, 2018, January 1, 2017 2015 14); 2016 08); 2016 10); 2016 10). May 2016, 2016 12, 606) May 2014. In August 2014, 2014 15, 205 40): December 31, 2016 December 31, 2016. 12 In July 2015, 2015 11, 2015 11”). 2015 11 first January 1, 2017 In February 2016, 2016 02, 842)”. December 15, 2018, In March 2016, 2016 09, 718): January 1, 2017 In August 2016, 2016 15, 230). zero December 15, 2017, In August 2016, 2016 18, 230). December 15, 2017,

Note 2 - Summary of Significa21

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, 2016 2015 Stock options to purchase common stock 1,909,764 1,022,195 Warrants to purchase common stock 425,274 383,321 Restricted common stock awards 58,155 -

Note 4 - Property and Equipme22

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	Life December 31, (in years) 2016 2015 Medical equipment 5 $ 657 $ 454 Computer equipment 3 83 56 Furniture and fixtures 7 57 24 797 534 Less: Accumulated depreciation and amortization (314 ) (295 ) Property and equipment, net $ 483 $ 239

Note 5 - Accrued Liabilities (T

Note 5 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, December 31, 2016 2015 Accrued bonuses $ 1,102 $ 613 Accrued professional fees 483 388 Accrued payroll and other related expenses 389 113 Accrued interest 65 22 Other accruals 147 157 Total accrued liabilities $ 2,186 $ 1,293

Note 6 - Note Payable (Tables)

Note 6 - Note Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2017 $ 2,719 2018 4,463 2019 4,512 Total payments 11,694 Less: Amount representing interest (1,694 ) Present value of obligations 10,000 Less: Unamortized debt discount (371 ) 9,629 Less: Note payable, noncurrent portion 7,762 Note payable, current portion $ 1,867

Note 7 - Commitments and Cont25

Note 7 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, 2017 $ 303 2018 82 Total minimum lease payments $ 385

Note 8 - Common Stock (Tables)

Note 8 - Common Stock (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 91,532 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 425,274

Note 9 - Summary of Stock Opt27

Note 9 - Summary of Stock Options (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Year Ended December 31, 2016 Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, beginning of period 1,022,195 $ 6.47 9.37 $ 1,194,180 Options granted 978,966 $ 6.00 Options exercised (3,020 ) $ 4.80 Options canceled (88,377 ) $ 7.41 Options outstanding, end of period 1,909,764 $ 6.19 9.12 $ 211,396 Vested and exercisable and expected to vest, end of period 1,761,430 $ 6.22 9.09 $ 204,619 Vested and exercisable, end of period 368,681 $ 7.51 8.04 $ 102,306
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices December 31, 2016 Price Term (Years) December 31, 2016 Price $2.64 12,500 $ 2.64 8.37 5,209 $ 2.64 $3.68 - $3.76 79,376 $ 3.75 8.10 36,382 $ 3.75 $4.80 - $4.92 197,969 $ 4.80 7.80 109,150 $ 4.80 $5.22 595,034 $ 5.22 9.98 7,250 $ 5.22 $6.00 565,628 $ 6.00 8.96 141,412 $ 6.00 $6.24 - $6.40 129,267 $ 6.35 9.15 - $ - $7.00 - $7.92 284,075 $ 7.71 9.49 23,363 $ 7.72 $9.92 38,135 $ 9.92 5.89 38,135 $ 9.92 $56.00 - $296.00 7,780 $ 83.66 0.83 7,780 $ 83.66 1,909,764 $ 6.19 9.12 368,681 $ 7.51
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2016 2015 Expected term (in years) 5 5 Average volatility 49 % 63 % Risk-free interest rate 1.78 % 1.70 % Dividend yield 0 % 0 % Year Ended December 31, 2016 Expected term (in years) 10 Average volatility 51 % Risk-free interest rate 2.43 % Dividend yield 0 %
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended December 31, 2016 2015 Research and development $ 114 $ 18 Selling, general and administrative 867 202 Total $ 981 $ 220

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2016 2015 Income tax provision (benefit) at statutory rate (34 )% (34 )% State income taxes, net of federal benefit (2 )% (6 )% Change in valuation allowance 33 % 39 % Other 3 % 1 % Effective tax rate - % - %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 16,888 $ 10,726 Capitalized start up costs 5,944 7,225 Research and development credits 518 248 Accruals and reserves 1,095 497 Total deferred tax assets 24,445 18,696 Deferred tax liabilities: Fixed assets and depreciation (7 ) (8 ) Valuation allowance (24,438 ) (18,688 ) Net deferred tax assets $ - $ -
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2016 2015 Balance at the beginning of the year $ 128 $ 97 Additions based upon tax positions related to the current year 140 31 Balance at the end of the year $ 268 $ 128

Note 12 - Segments and Geogra29

Note 12 - Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2016 2015 Asia $ 4,946 889 Europe and Middle East 1,489 551 Latin America 382 - United States 315 - Canada 9 5 Other - 2 Total $ 7,141 $ 1,447
Long-lived Assets by Geographic Areas [Table Text Block]	Year Ended December 31, 2016 2015 United States $ 370 $ 100 Europe 72 99 Asia 39 32 Canada 2 8 Total $ 483 $ 239

Note 1 - The Company and Basi30

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Jun. 17, 2016	Nov. 24, 2015	May 14, 2015	Dec. 31, 2016	Dec. 31, 2015	May 29, 2016	Dec. 31, 2014
Proceeds from Issuance of Common Stock				$ 13,886,000	$ 16,433,000
Common Stock, Par or Stated Value Per Share						$ 0.0001
Proceeds from Issuance Of Private Placement Gross		$ 6,000,000	$ 12,000,000
Proceeds from Issuance of Private Placement Net		$ 5,393,000	$ 11,040,000
Cash and Cash Equivalents, at Carrying Value				8,086,000	7,360,000		$ 895,000
Working Capital				6,791,000
Retained Earnings (Accumulated Deficit)				$ (68,622,000)	$ (48,511,000)
June 2016 Offering [Member]
Stock Issued During Period, Shares, New Issues	3,105,000
Share Price	$ 5
Proceeds from Issuance of Common Stock	$ 15,525,000
Proceeds From Issuance of Common Stock, Net	$ 13,886,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		1,071,679	4,054,062
Share Price		$ 5.60	$ 2.96

Note 2 - Summary of Significa31

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Apr. 15, 2016	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Number of Financial Institutions			1
Allowance for Doubtful Accounts Receivable			$ 0	$ 0
Inventory, Raw Materials, Net of Reserves			181,000
Inventory, Finished Goods, Net of Reserves			$ 2,506,000
Warranty Period			1 year
Minimum [Member]
Property, Plant and Equipment Estimated Useful Lives1			3 years
Maximum [Member]
Property, Plant and Equipment Estimated Useful Lives1			7 years
Medical Equipment, Sales Demos [Member]
Property, Plant and Equipment Estimated Useful Lives1			5 years
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Number of Customers			3	4
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Three Customers [Member]
Concentration Risk, Percentage			78.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Four Customers [Member]
Concentration Risk, Percentage				87.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers			3	3
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage			81.00%	86.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	8
Reclassification to Report Debt Issuance Costs as a Contra Debt Liability [Member] | December 31, 2015 [Member]
Prior Period Reclassification Adjustment		$ (387,000)

Note 2 - Summary of Significa32

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	1,909,764	1,022,195
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	425,274	383,321
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	58,155	0

Note 4 - Property and Equipme33

Note 4 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Depreciation	$ 111,000	$ 77,000

Note 4 - Property and Equipme34

Note 4 - Property and Equipment, Net - Equipment, Furniture, and Leasehold Improvements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property and equipment, gross	$ 797	$ 534
Less: Accumulated depreciation and amortization	(314)	(295)
Property and equipment, net	$ 483	239
Equipment [Member]
Useful life (Year)	5 years
Property and equipment, gross	$ 657	454
Computer Equipment [Member]
Useful life (Year)	3 years
Property and equipment, gross	$ 83	56
Furniture and Fixtures [Member]
Useful life (Year)	7 years
Property and equipment, gross	$ 57	$ 24

Note 5 - Accrued Liabilities -

Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued bonuses	$ 1,102	$ 613
Accrued professional fees	483	388
Accrued payroll and other related expenses	389	113
Accrued interest	65	22
Other accruals	147	157
Total accrued liabilities	$ 2,186	$ 1,293

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual) - USD ($)	Jun. 20, 2016	Jul. 15, 2015	Apr. 06, 2015	Mar. 16, 2015	Feb. 19, 2015	Oct. 01, 2014	Sep. 30, 2014	May 31, 2015	Nov. 30, 2014	Dec. 31, 2016	Feb. 28, 2015
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									47,751	425,274	75,697
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 4.24		$ 4
Warrant Term									5 years
September 2014 Issuance Related to 2014 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							58,962
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 4.24
Warrant Term							10 years	10 years
May 2015 Issuance Related to 2014 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								3,125
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 2.96
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	100,402									100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.98									$ 4.98
Warrant Term	10 years
September 2014 Term Loan [Member]
Debt Instrument, Face Amount							$ 5,000,000
September 2014 Term Loan [Member] | First Tranche [Member]
Proceeds from Loans						$ 2,500,000
September 2014 Term Loan [Member] | Second Tranche [Member]
Debt Instrument, Face Amount							$ 1,500,000
Proceeds from Loans			$ 500,000	$ 500,000	$ 500,000
September 2014 Term Loan [Member] | Third Tranche [Member]
Proceeds from Loans		$ 1,000,000
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member]
Debt Instrument, Face Amount	$ 10,000,000
Debt Instrument Repayment Of Principal And Interest Number Of Installments	30
Debt Instrument, Interest Rate, Effective Percentage										7.59%
Debt Instrument, Covenant, Actual Performance Revenue to Planned Revenue, Minimum, Percentage										80.00%
Debt Instrument, Covenant, Unrestricted Cash in Accounts to Indebtedness Ratio										1.25
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage	7.40%
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	6.96%
The 2016 Loan Agreement [Member] | First Tranche [Member] | Western Alliance Bank [Member]
Proceeds from Issuance of Long-term Debt	$ 7,500,000
The 2016 Loan Agreement [Member] | Second Tranche [Member] | Western Alliance Bank [Member]
Proceeds from Issuance of Long-term Debt	$ 2,500,000

Note 6 - Note Payable - Summary

Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
2,017	$ 2,719
2,018	4,463
2,019	4,512
Total payments	11,694
Less: Amount representing interest	(1,694)
Present value of obligations	10,000
Less: Unamortized debt discount	(371)
	9,629
Less: Note payable, noncurrent portion	7,762	$ 0
Note payable, current portion	$ 1,867	$ 4,446

Note 7 - Commitments and Cont38

Note 7 - Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Leases, Rent Expense	$ 236,000	$ 210,000

Note 7 - Commitments and Cont39

Note 7 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2016USD ($)
2,017	$ 303
2,018	82
Total minimum lease payments	$ 385

Note 8 - Common Stock (Details

Note 8 - Common Stock (Details Textual) - USD ($)	Jun. 20, 2016	Jun. 17, 2016	Nov. 24, 2015	May 14, 2015	Mar. 31, 2015	Sep. 30, 2014	Aug. 30, 2016	Jul. 31, 2016	May 31, 2016	Apr. 30, 2016	Dec. 31, 2015	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014	Dec. 31, 2016	Dec. 31, 2015
Proceeds from Issuance of Common Stock															$ 13,886,000	$ 16,433,000
Proceeds from Issuance of Private Placement Net			$ 5,393,000	$ 11,040,000
Proceeds from Issuance Of Private Placement Gross			$ 6,000,000	$ 12,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights													75,697	47,751	425,274
Class of Warrant or Right, Exercise Price of Warrants or Rights													$ 4	$ 4.24
Warrant Term														5 years
Allocated Share-based Compensation Expense															$ 981,000	$ 220,000
The 2016 Loan Agreement [Member]
Amortization of Debt Discount (Premium)															69,000
Debt Issuance Costs, Net															90,000
Unamortized Debt Issuance Expense															$ 371,000
Vendors And Nonemployee [Member]
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period															1,094	5,157
Warrant [Member]
Fair Value Assumptions, Expected Dividend Rate													0.00%	0.00%
Fair Value Assumptions, Expected Volatility Rate													77.60%	61.30%
Fair Value Assumptions, Risk Free Interest Rate													2.14%
Fair Value Assumptions, Expected Term													10 years
Warrant [Member] | Minimum [Member]
Fair Value Assumptions, Risk Free Interest Rate														1.55%
Warrant [Member] | Maximum [Member]
Fair Value Assumptions, Risk Free Interest Rate														1.65%
September 2014 Issuance Related to 2014 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						58,962
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 4.24
Warrant Term						10 years						10 years
Stock Issued During Period, Shares, Exercise of Warrants							17,295
Warrants and Rights Outstanding						$ 622,000
Fair Value Assumptions, Expected Dividend Rate						0.00%
Fair Value Assumptions, Expected Volatility Rate						77.00%
Fair Value Assumptions, Risk Free Interest Rate						2.50%
Amortization of Debt Discount (Premium)															$ 387,000	$ 187,000
March 2015 Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,454
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 2.72
Warrant Term					10 years
Fair Value Assumptions, Expected Dividend Rate					0.00%
Fair Value Assumptions, Expected Volatility Rate					78.90%
Fair Value Assumptions, Risk Free Interest Rate					1.94%
May 2015 Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					36,229
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 4.24
Warrant Term					10 years
Fair Value Assumptions, Expected Dividend Rate					0.00%
Fair Value Assumptions, Expected Volatility Rate					80.10%
Fair Value Assumptions, Risk Free Interest Rate					2.28%
May 2015 Issuance Related to 2014 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												3,125
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 2.96
Stock Issued During Period, Shares, Exercise of Warrants								885
Amortization of Debt Discount (Premium)																$ 10,000
May 2015 Issuance Second Contractor [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												21,585			21,585
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 4.24			$ 4.24
Warrant Term												5 years
Fair Value Assumptions, Expected Dividend Rate												0.00%
Fair Value Assumptions, Expected Volatility Rate												64.40%
Fair Value Assumptions, Risk Free Interest Rate												1.54%
December 2015 Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											26,875					26,875
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 5.60					$ 5.60
Warrant Term											10 years
Fair Value Assumptions, Expected Dividend Rate											0.00%
Fair Value Assumptions, Expected Volatility Rate											76.80%
Fair Value Assumptions, Risk Free Interest Rate											2.27%
Distributor Warrants, March 2016 Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										25,000					25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 6.08					$ 6.08
Warrant Term										10 years
Fair Value Assumptions, Expected Dividend Rate										0.00%
Fair Value Assumptions, Expected Volatility Rate										72.10%
Fair Value Assumptions, Risk Free Interest Rate										1.78%
Allocated Share-based Compensation Expense															$ 162,000	$ 537,000
Contractor Warrants, May 2016 Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									5,000						5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 7.74						$ 7.74
Warrant Term									5 years
Fair Value Assumptions, Expected Dividend Rate									0.00%
Fair Value Assumptions, Expected Volatility Rate									61.60%
Fair Value Assumptions, Risk Free Interest Rate									1.20%
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	100,402														100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.98														$ 4.98
Warrant Term	10 years
Warrants and Rights Outstanding	$ 350,000
Fair Value Assumptions, Expected Dividend Rate	0.00%
Fair Value Assumptions, Expected Volatility Rate	63.00%
Fair Value Assumptions, Risk Free Interest Rate	1.67%
June 2016 Offering [Member]
Stock Issued During Period, Shares, New Issues		3,105,000
Share Price		$ 5
Proceeds from Issuance of Common Stock		$ 15,525,000
Proceeds From Issuance of Common Stock, Net		$ 13,886,000
November 2015 Private Placement Offering [Member]
Stock Issued During Period, Shares, New Issues			1,071,679
Share Price			$ 5.60
Proceeds From Issuance of Common Stock, Gross			$ 6,000,000
Proceeds from Issuance of Private Placement Net			$ 5,393,000
May 2015 Issuance [Member]
Stock Issued During Period, Shares, New Issues				4,054,062
Proceeds From Issuance of Common Stock, Net				$ 11,040,000
Proceeds From Issuance of Common Stock, Gross				12,000,000
Proceeds from Issuance Of Private Placement Gross				$ 2.96
Private Placement [Member]
Stock Issued During Period, Shares, New Issues			1,071,679	4,054,062
Share Price			$ 5.60	$ 2.96
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						117,535
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 4.24
Warrant Term						5 years
Class of Warrants or Rights, Exercises in Period															25,268	735
Stock Issued During Period, Shares, Exercise of Warrants															23,560

Note 8 - Common Stock - Summary

Note 8 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Jun. 20, 2016	May 31, 2016	Apr. 30, 2016	May 31, 2015	Feb. 28, 2015	Nov. 30, 2014
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 4	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	425,274					75,697	47,751
September 2014 Issuance Through Private Offering [Member]
Expiration Date	Sep. 23, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	91,532
Vendors and Contractor Warrants, October 2014 Issuance [Member]
Expiration Date	Oct. 13, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	29,000
Vendors and Contractor Warrants, November 2014 Issuance [Member]
Expiration Date	Nov. 12, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	12,500
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	75,697
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.72
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,454
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	36,229
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24				$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	21,585				21,585
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	26,875
Distributor Warrants, March 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.08			$ 6.08
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	25,000			25,000
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.74		$ 7.74
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000		5,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.98	$ 4.98
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	100,402	100,402

Note 9 - Summary of Stock Opt42

Note 9 - Summary of Stock Options (Details Textual) - USD ($)	Dec. 23, 2016	Aug. 22, 2016	Nov. 30, 2016	Sep. 30, 2016	Aug. 31, 2016	Jan. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Aug. 21, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number							1,909,764	1,022,195
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price							$ 6.19	$ 6.47
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term							9 years 43 days	9 years 135 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							978,966
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							3,020
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options							$ 3,757,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							3 years 98 days
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate							0.00%	0.00%
Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate							0.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate							0.00%
Two Thousand Five Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance							1,892
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number							1,892
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price							$ 116.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term							266 days
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number							38,378
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price							$ 10.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term							5 years 321 days
Conversion of Stock Exchange Ratio							0.0080497
Conversion of Stock, Post Revenue Stock Split Basis, Ratio							0.0010062
The 2013 Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance							10,236
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number							1,869,494
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price							$ 5.99
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term							9 years 69 days
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							4 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum							10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent							110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Period Increase (Decrease)		737,500
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		2,000,000							1,262,500
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percentage Increase of Outstanding Common Stock	4.00%	4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	523,209
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							919,841	753,880
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 2.63	$ 3.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value							$ 5,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period								0
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							59,125	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 4.60
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							0	0
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number							58,155
The 2013 Plan [Member] | Restricted Stock [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period						39,494
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value						$ 6.24
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period							0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period				89
The 2013 Plan [Member] | Restricted Stock [Member] | Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			6,544		5,998
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 5.91		$ 7.89
The 2013 Plan [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				1 year
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				25,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 7.58
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period							6,250
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							5 years
The 2013 Plan [Member] | Quarterly [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				25.00%

Note 9 - Summary of Stock Opt43

Note 9 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Options outstanding, Shares (in shares)	1,022,195
Options outstanding, Weighted average exercise price (in dollars per share)	$ 6.47
Options outstanding, weighted average remaining contractual term (Year)	9 years 43 days	9 years 135 days
Options outstanding, Aggregate Intrinsic Value	$ 211,396,000	$ 1,194,180
Options granted, Shares (in shares)	978,966
Options granted, Weighted average exercise price (in dollars per share)	$ 6
Options exercised, Shares (in shares)	(3,020)
Options exercised, Weighted average exercise price (in dollars per share)	$ 4.80
Options canceled, Shares (in shares)	(88,377)
Options canceled, Weighted average exercise price (in dollars per share)	$ 7.41
Options outstanding, Shares (in shares)	1,909,764	1,022,195
Options outstanding, Weighted average exercise priceod (in dollars per share)	$ 6.19	$ 6.47
Vested and exercisable and expected to vest, end of period, Number Of Shares (in shares)	1,761,430
Vested and exercisable and expected to vest, end of period, Weighted Average Exercise Price (in dollars per share)	$ 6.22
Vested and exercisable and expected to vest, end of period, Weighted Average Remaining Contractual Term (Year)	9 years 32 days
Vested and exercisable and expected to vest, end of period, Aggregate Intrinsic Value	$ 204,619,000
Vested and exercisable, end of period, Number Of Shares (in shares)	368,681
Vested and exercisable, end of period, Weighted Average Exercise Price (in dollars per share)	$ 7.51
Vested and exercisable, end of period, Weighted Average Remaining Contractual Term (Year)	8 years 14 days
Vested and exercisable, end of period, Aggregate Intrinsic Value	$ 102,306,000

Note 9 - Summary of Stock Opt44

Note 9 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 6.19
Options Outstanding, Number (in shares) | shares	1,909,764
Options Outstanding - Weighted Average Remaining Contractual Term (Year)	9 years 43 days
Options Exercisable - Number (in shares) | shares	368,681
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 7.51
Range One [Member]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 2.64
Options Outstanding, Number (in shares) | shares	12,500
Options Outstanding - Weighted Average Remaining Contractual Term (Year)	8 years 135 days
Options Exercisable - Number (in shares) | shares	5,209
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 2.64
Range Two [Member]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 3.75
Options Outstanding, Number (in shares) | shares	79,376
Options Outstanding - Weighted Average Remaining Contractual Term (Year)	8 years 36 days
Options Exercisable - Number (in shares) | shares	36,382
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 3.75
Range of Exercise Prices, Lower Range (in dollars per share)	3.68
Range of Exercise Prices, Upper Range (in dollars per share)	3.76
Range Three [Member]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 4.80
Options Outstanding, Number (in shares) | shares	197,969
Options Outstanding - Weighted Average Remaining Contractual Term (Year)	7 years 292 days
Options Exercisable - Number (in shares) | shares	109,150
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 4.80
Range of Exercise Prices, Lower Range (in dollars per share)	4.80
Range of Exercise Prices, Upper Range (in dollars per share)	4.92
Range Four [Member]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 5.22
Options Outstanding, Number (in shares) | shares	595,034
Options Outstanding - Weighted Average Remaining Contractual Term (Year)	9 years 357 days
Options Exercisable - Number (in shares) | shares	7,250
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 5.22
Range Five [Member]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 6
Options Outstanding, Number (in shares) | shares	565,628
Options Outstanding - Weighted Average Remaining Contractual Term (Year)	8 years 350 days
Options Exercisable - Number (in shares) | shares	141,412
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 6
Range Six [Member]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 6.35
Options Outstanding, Number (in shares) | shares	129,267
Options Outstanding - Weighted Average Remaining Contractual Term (Year)	9 years 54 days
Options Exercisable - Number (in shares) | shares
Options Exercisable - Weighted Average Exercise Price (in dollars per share)
Range of Exercise Prices, Lower Range (in dollars per share)	6.24
Range of Exercise Prices, Upper Range (in dollars per share)	6.40
Range Seven [Member]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 7.71
Options Outstanding, Number (in shares) | shares	284,075
Options Outstanding - Weighted Average Remaining Contractual Term (Year)	9 years 178 days
Options Exercisable - Number (in shares) | shares	23,363
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 7.72
Range of Exercise Prices, Lower Range (in dollars per share)	7
Range of Exercise Prices, Upper Range (in dollars per share)	7.92
Range Eight [Member]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 9.92
Options Outstanding, Number (in shares) | shares	38,135
Options Outstanding - Weighted Average Remaining Contractual Term (Year)	5 years 324 days
Options Exercisable - Number (in shares) | shares	38,135
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 9.92
Range Nine [Member]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 83.66
Options Outstanding, Number (in shares) | shares	7,780
Options Outstanding - Weighted Average Remaining Contractual Term (Year)	302 days
Options Exercisable - Number (in shares) | shares	7,780
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 83.66
Range of Exercise Prices, Lower Range (in dollars per share)	56
Range of Exercise Prices, Upper Range (in dollars per share)	$ 296

Note 9 - Summary of Stock Opt45

Note 9 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employees [Member]
Expected term (in years) (Year)	5 years	5 years
Average volatility	49.00%	63.00%
Risk-free interest rate	1.78%	1.70%
Dividend yield	0.00%	0.00%
Nonemployees [Member]
Expected term (in years) (Year)	10 years
Average volatility	51.00%
Risk-free interest rate	2.43%
Dividend yield	0.00%

Note 9 - Summary of Stock Opt46

Note 9 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Allocated share-based compensation expense	$ 981	$ 220
Research and Development Expense [Member]
Allocated share-based compensation expense	114	18
General and Administrative Expense [Member]
Allocated share-based compensation expense	$ 867	$ 202

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 5,750,000	$ 4,822,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	518,000	248,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	0
Unrecognized Tax Benefits	268,000	$ 128,000	$ 97,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards	45,468,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	440,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	24,498,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 454,000

Note 10 - Income Taxes - Provis

Note 10 - Income Taxes - Provision for Income Taxes Computed at Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income tax provision (benefit) at statutory rate	(34.00%)	(34.00%)
State income taxes, net of federal benefit	(2.00%)	(6.00%)
Change in valuation allowance	33.00%	39.00%
Other	3.00%	1.00%
Effective tax rate

Note 10 - Income Taxes - Signif

Note 10 - Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 16,888	$ 10,726
Capitalized start up costs	5,944	7,225
Research and development credits	518	248
Accruals and reserves	1,095	497
Total deferred tax assets	24,445	18,696
Deferred tax liabilities:
Fixed assets and depreciation	(7)	(8)
Valuation allowance	$ (24,438)	$ (18,688)

Note 10 - Income Taxes - Unreco

Note 10 - Income Taxes - Unrecognized Tax Benefit Roll Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Balance	$ 128,000	$ 97,000
Additions based upon tax positions related to the current year	140,000	31,000
Balance	$ 268,000	$ 128,000

Note 11 - Related Party Trans51

Note 11 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	Oct. 04, 2007	Dec. 31, 2016	Dec. 31, 2015
Stock Issued During Period, Shares, New Issues	37,500
Related Party Transaction, Amounts of Transaction		$ 6,485,000	$ 3,446,000

Note 12 - Segments and Geogra52

Note 12 - Segments and Geographic Information - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue	$ 7,141	$ 1,447
Asia [Member]
Revenue	4,946	889
Europe And Middle East [Member]
Revenue	1,489	551
Latin America [Member]
Revenue	382
UNITED STATES
Revenue	315
CANADA
Revenue	9	5
Other [Member]
Revenue		$ 2

Note 12 - Long-lived Assets by

Note 12 - Long-lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property and equipment, net	$ 483	$ 239
UNITED STATES
Property and equipment, net	370	100
Europe [Member]
Property and equipment, net	72	99
Asia [Member]
Property and equipment, net	39	32
CANADA
Property and equipment, net	$ 2	$ 8

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - Subsequent Event [Member]	Jan. 13, 2017USD ($)	Jan. 01, 2017USD ($)a$ / ft²
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property | a		12,400
Operating Leases of Lessee, Period Following Delivery of Possession Triggering Commencement		120 days
Lessee Leasing Arrangements, Operating Leases, Term of Contract		3 years
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | $ / ft²		20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | $ / ft²		21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | $ / ft²		21.75
Security Deposit | $		$ 22,000
Operating Leases, Allowance for Certain Improvements | $		$ 88,000
First Amendment to the 2016 Loan Agreement [Member] | Western Alliance Bank [Member]
Debt Instrument, Covenant, Unrestricted Cash in Accounts to Indebtedness Ratio	1.25
First Amendment to the 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | Minimum [Member]
Debt Instrument, Covenant, Minimum Unrestricted Cash in Accounts | $	$ 2,000,000